Trevena, Inc. (TRVN)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
TRVN Insider Trading Activity
TRVN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
About Trevena, Inc.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor …
Insider Activity of Trevena, Inc.
Over the last 12 months, insiders at Trevena, Inc. have bought $0 and sold $0 worth of Trevena, Inc. stock.
On average, over the past 5 years, insiders at Trevena, Inc. have bought $100,542 and sold $13,032 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 56,200 shares for transaction amount of $100,542 was made by Bourdow Carrie L. (President & CEO) on 2021‑06‑28.
List of Insider Buy and Sell Transactions, Trevena, Inc.
| 2022-06-28 | Sale | Shin Barry | SVP, CFO | 31,785 0.0191% | $0.41 | $13,032 | -81.99% | |
| 2021-06-28 | Bourdow Carrie L. | President & CEO | 56,200 0.0342% | $1.79 | $100,542 | -64.44% | ||
| 2019-05-31 | Hamill John P. | VP Fin,Princ Fin&Acct Officer | 15,000 0.0081% | $0.58 | $8,700 | -23.88% | ||
| 2019-02-01 | MOULDER LEON O JR | director | 200,000 0.2272% | $1.02 | $204,000 | -2.97% | ||
| 2019-02-01 | GOWEN MAXINE | President & CEO | 100,000 0.1136% | $1.02 | $102,000 | -2.97% | ||
| 2018-03-22 | Sale | Habib Yacoub | SVP, Bus Dev & Corp Planning | 10,000 0.0154% | $1.76 | $17,600 | -15.25% | |
| 2017-02-10 | Sale | Lark Michael W. | Sr. VP, Research & CSO | 47,398 0.0848% | $8.00 | $379,184 | -68.58% | |
| 2016-11-09 | Bourdow Carrie L. | SVP, Chief Commercial Officer | 8,000 0.0147% | $4.34 | $34,720 | -29.31% | ||
| 2016-11-07 | GOWEN MAXINE | President & CEO | 25,000 0.0488% | $4.10 | $102,500 | -19.45% | ||
| 2016-11-07 | Habib Yacoub | SVP, Bus Dev & Corp Planning | 10,000 0.0196% | $4.12 | $41,200 | -19.45% | ||
| 2016-05-27 | GOWEN MAXINE | President & CEO | 28,168 0.0541% | $7.08 | $199,429 | -12.32% | ||
| 2016-05-26 | GOWEN MAXINE | President & CEO | 16,000 0.0311% | $7.20 | $115,120 | -12.68% | ||
| 2015-12-10 | Sale | Soergel David | Sr. VP,Clinical Dev. & CMO | 54,434 0.1227% | $10.55 | $574,279 | -34.14% | |
| 2014-12-12 | Limongelli John M | Sr. VP,General Counsel & Secy | 6,000 0.0251% | $4.14 | $24,840 | +68.58% | ||
| 2014-12-10 | New Enterprise Associates 12, Limited Partnership | director | 2M 7.9332% | $4.00 | $8M | +64.91% | ||
| 2014-12-10 | Alta Partners VIII, L.P. | director | 1M 3.9666% | $4.00 | $4M | +64.91% | ||
| 2014-12-10 | GOWEN MAXINE | President & CEO | 16,000 0.0635% | $4.00 | $64,000 | +64.91% | ||
| 2014-12-10 | Lark Michael W. | Sr. VP, Research & CSO | 10,000 0.0397% | $4.00 | $40,000 | +64.91% | ||
| 2014-12-10 | MOULDER LEON O JR | director | 19,800 0.0797% | $4.06 | $80,388 | +64.91% | ||
| 2014-12-10 | Soergel David | Sr. VP, Clinical Development | 1,250 0.005% | $4.00 | $5,000 | +64.91% |
Insider Historical Profitability
| New Enterprise Associates 12, Limited Partnership | director | 4811691 557.0452% | $6.54M | 2 | 1 | |
| Alta Partners VIII, L.P. | director | 4390262 508.2567% | $5.97M | 2 | 0 | |
| Forest Laboratories Holdings Ltd | director | 3393466 392.8586% | $4.62M | 1 | 0 | |
| HealthCare Ventures VIII, L.P. | director | 2446251 283.2003% | $3.33M | 1 | 0 | |
| Bourdow Carrie L. | President & CEO | 1301510 150.6747% | $1.77M | 2 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$1,138,733 | 28 | -4.94% | $2.79M | |
$63,749,694 | 24 | -12.24% | $2.29M | |
$193,112 | 22 | -20.59% | $1.68M | |
$1,616,354 | 20 | -12.22% | $3.25M | |
$613,181 | 18 | -20.90% | $2.12M |
TRVN Institutional Investors: Active Positions
| Increased Positions | <1 | company.increased | <1 | company.increased |
| Decreased Positions | <1 | company.decreased | <1 | company.decreased |
| New Positions | <1 | New | <1 | New |
| Sold Out Positions | <1 | Sold Out | <1 | Sold Out |
| Total Postitions | <1 | company.total | <1 | company.total |